Evaluation of Glycomic Profiling as a Diagnostic Biomarker for Epithelial Ovarian Cancer

Background: Prior studies suggested that glycans were differentially expressed in patients with ovarian cancer and controls. We hypothesized that glycan-based biomarkers might serve as a diagnostic test for ovarian cancer and evaluated the ability of glycans to distinguish ovarian cancer cases from matched controls. Methods: Serum samples were obtained from the tissue-banking repository of the Gynecologic Oncology Group, and included healthy female controls (n = 100), women diagnosed with low malignant potential (LMP) tumors (n = 52), and epithelial ovarian cancers (EOC) cases (n = 147). Cases and controls were matched on age at enrollment within ±5 years. Serum samples were analyzed by glycomics analysis to detect abundance differences in glycan expression levels. A two-stage procedure was carried out for biomarker discovery and validation. Candidate classifiers of glycans that separated cases from controls were developed using a training set in the discovery phase and the classification performance of the candidate classifiers was assessed using independent test samples that were not used in discovery. Results: The patterns of glycans showed discriminatory power for distinguishing EOC and LMP cases from controls. Candidate glycan-based biomarkers developed on a training set (sensitivity, 86% and specificity, 95.8% for distinguishing EOC from controls through leave-one-out cross-validation) confirmed their potential use as a detection test using an independent test set (sensitivity, 70% and specificity, 86.5%). Conclusion: Formal investigations of glycan biomarkers that distinguish cases and controls show great promise for an ovarian cancer diagnostic test. Further validation of a glycan-based test for detection of ovarian cancer is warranted. Impact: An emerging diagnostic test based on the knowledge gained from understanding the glycobiology should lead to an assay that improves sensitivity and specificity and allows for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev; 23(4); 611–21. ©2014 AACR.

[1]  Yung-Hun Yang,et al.  Rapid and high-throughput analysis of N-glycans from ovarian cancer serum using a 96-well plate platform. , 2009, Analytical biochemistry.

[2]  J. Lancaster,et al.  The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. , 2012, International journal of oncology.

[3]  L. R. Ruhaak,et al.  Developments in the Identification of Glycan Biomarkers for the Detection of Cancer , 2013, Molecular & Cellular Proteomics.

[4]  K. Lam,et al.  Glycomics analysis of serum: a potential new biomarker for ovarian cancer? , 2007, International Journal of Gynecologic Cancer.

[5]  André M Deelder,et al.  IgG glycosylation analysis , 2009, Proteomics.

[6]  Scott R. Kronewitter,et al.  The glycolyzer: Automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery , 2012, Proteomics.

[7]  H. An,et al.  Glycoscience aids in biomarker discovery. , 2012, BMB reports.

[8]  Kiyoko F. Aoki-Kinoshita,et al.  Frontiers in glycomics: Bioinformatics and biomarkers in disease An NIH White Paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11–13, 2006) , 2008, Proteomics.

[9]  C. Lebrilla,et al.  Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. , 2013, Journal of chromatography. A.

[10]  Pauline M. Rudd,et al.  Glycosylation Changes on Serum Glycoproteins in Ovarian Cancer May Contribute to Disease Pathogenesis , 2009, Disease markers.

[11]  Steven J Skates,et al.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. , 2010, American journal of obstetrics and gynecology.

[12]  C. Lebrilla,et al.  Annotation of a serum N-glycan library for rapid identification of structures. , 2012, Journal of proteome research.

[13]  Kyoungmi Kim,et al.  A Jackknife and Voting Classifier Approach to Feature Selection and Classification , 2011, Cancer informatics.

[14]  W. Alley,et al.  N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. , 2012, Journal of proteome research.

[15]  Jill P. Mesirov,et al.  Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.

[16]  R. A. van den Berg,et al.  Centering, scaling, and transformations: improving the biological information content of metabolomics data , 2006, BMC Genomics.

[17]  James C Paulson,et al.  Frontiers in Glycomics; Bioinformatics and Biomarkers in Disease September 11‐13, 2006 Natcher Conference Center, NIH Campus, Bethesda, MD, USA , 2007, Proteomics.

[18]  Yehia Mechref,et al.  Identifying cancer biomarkers by mass spectrometry‐based glycomics , 2012, Electrophoresis.

[19]  R. Dwek,et al.  GALACTOSYLATION OF IgG ASSOCIATED OLIGOSACCHARIDES: REDUCTION IN PATIENTS WITH ADULT AND JUVENILE ONSET RHEUMATOID ARTHRITIS AND RELATION TO DISEASE ACTIVITY , 1988, The Lancet.

[20]  S. Kornfeld,et al.  Assembly of asparagine-linked oligosaccharides. , 1985, Annual review of biochemistry.

[21]  C. Lebrilla,et al.  A glycomics approach to the discovery of potential cancer biomarkers. , 2010, Methods in molecular biology.

[22]  Scott R. Kronewitter,et al.  The development of retrosynthetic glycan libraries to profile and classify the human serum N‐linked glycome , 2009, Proteomics.

[23]  C. Lebrilla,et al.  Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. , 2011, The Analyst.

[24]  Pauline M Rudd,et al.  Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. , 2007, Glycobiology.

[25]  Károly Héberger,et al.  Mass spectrometric and linear discriminant analysis of N-glycans of human serum alpha-1-acid glycoprotein in cancer patients and healthy individuals. , 2008, Journal of proteomics.

[26]  Scott R. Kronewitter,et al.  Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling. , 2010, Journal of proteome research.